A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy

Last updated: December 12, 2024
Sponsor: Tris Pharma, Inc.
Overall Status: Active - Recruiting

Phase

3

Condition

Pain

Acute Pain

Treatment

Oxycodone IR

Placebo

Cebranopadol

Clinical Study ID

NCT06423703
TRN-228-302
  • Ages 18-75
  • All Genders

Study Summary

The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a bunionectomy.

Eligibility Criteria

Inclusion

Key Inclusion Criteria Before Surgery:

  • Scheduled to undergo primary unilateral bunionectomy with first metatarsal osteotomyand internal fixation with no collateral procedures, using anesthesiologic andsurgical procedures planned.

  • Must be able to adhere to the visit schedule, complete all study assessments andprotocol requirements, including self-reported questionnaires.

Key Exclusion Criteria Before Surgery:

  • Any clinically significant disease, medical condition, or laboratory finding that inthe investigator's opinion may interfere with the study procedures or dataintegrity, or compromise the safety of the subject.

  • Secondary (i.e., unrelated to bunion) current painful condition that could confoundthe interpretation of efficacy, safety, or tolerability data in the study, in theopinion of the investigator.

  • Subjects who require any analgesic for secondary (i.e., unrelated to bunion) painfulcondition that might impact the subject's ability to properly assess theirpostoperative pain, or that may require treatment during the Treatment Phase.

  • History of allergy or hypersensitivity to any opioid analgesics, anesthetics,ibuprofen, or other NSAIDs.

Exclusion

Immediate Postoperative Exclusion Criteria:

  • Surgical, postsurgical, or anesthetic complication that could confound theinterpretation of efficacy, safety, or tolerability data in the study.

  • Deviation from the surgical, postsurgical, or anesthetic protocol that couldconfound the interpretation of efficacy, safety, or tolerability data in the study.

  • Evidence of hemodynamic instability or respiratory insufficiency.

Study Design

Total Participants: 240
Treatment Group(s): 3
Primary Treatment: Oxycodone IR
Phase: 3
Study Start date:
July 18, 2024
Estimated Completion Date:
March 31, 2025

Study Description

This study is a Phase 3, multicenter, randomized, double-blind, placebo- and active-controlled parallel-group study to evaluate the efficacy and safety of cebranopadol in the treatment of postoperative pain following primary unilateral bunionectomy with first metatarsal osteotomy. The study will be conducted in 3 phases: Screening, Treatment, and Follow-up.

Connect with a study center

  • ALLEVIATE 2 Site 001108

    Sheffield, Alabama 35660
    United States

    Active - Recruiting

  • ALLEVIATE 2 Site 001106

    Little Rock, Arkansas 72211
    United States

    Active - Recruiting

  • ALLEVIATE 2 Site 001103

    Tampa, Florida 33613
    United States

    Active - Recruiting

  • ALLEVIATE 2 Site 001102

    Atlanta, Georgia 30331
    United States

    Active - Recruiting

  • ALLEVIATE 2 Site 001107

    Overland Park, Kansas 66212
    United States

    Active - Recruiting

  • ALLEVIATE 2 Site 001105

    Pasadena, Maryland 21122
    United States

    Active - Recruiting

  • Alleviate 2 001113

    Houston, Texas 77043
    United States

    Active - Recruiting

  • ALLEVIATE 2 Site 001104

    McAllen, Texas 78501
    United States

    Active - Recruiting

  • ALLEVIATE 2 Site 001111

    San Antonio, Texas 78240
    United States

    Active - Recruiting

  • ALLEVIATE 2 Site 001101

    Salt Lake City, Utah 84107
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.